Compare Expensify Inc (EXFY) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Nuwellis Inc — how do they compare? Expensify Inc trades at $2.3 (market cap $208.82M), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: Expensify Inc is far larger — about 94.9× Nuwellis Inc's market cap, and Expensify Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Expensify Inc for 41 Days and Nuwellis Inc for 26 Days on average.
| EXFY | NUWE | |
|---|---|---|
Market Cap | $208.82M | $2.20M |
Volume | 456,102 | 121,544 |
Sector | Technology | Health |
52-Week High | $2.72 | $146.65 |
52-Week Low | $0.75 | $0.68 |
Typical Hold Time | 41 Days | 26 Days |
Enterprise Value | $148.44M | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.27, up 1.79% with a neutral technical signal. The company shows mixed fundamentals with revenue stabilizing around $140M but persistent net losses. Recent quarters show earnings improvement with two beats, while analyst consensus is bullish with a $13.75 price target. Business developments include AI integrations and European expansion of corporate card offerings.
The outlook remains speculative given negative profitability metrics, though cash flow improvements and strategic partnerships provide potential catalysts. Key risks include competitive pressure in expense management and the challenge of achieving sustainable profitability. The significant gap between current price and analyst targets suggests upside potential if execution improves.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
